Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Chesney, Jason; Puzanov, Igor; Collichio, Frances; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore F.; Hauschild, Axel; Lebbe, Celeste; Chen, Lisa; Kim, Jenny J.; Gansert, Jennifer; Andtbacka, Robert H. I.; Kaufman, Howard L.

dc.contributor.author	Garbe, Claus
dc.date.accessioned	2019-09-10T12:29:13Z
dc.date.available	2019-09-10T12:29:13Z
dc.date.issued	2018
dc.identifier.issn	1527-7755
dc.identifier.uri	http://hdl.handle.net/10900/92620
dc.language.iso	en	de_DE
dc.publisher	Amer Soc Clinical Oncology	de_DE
dc.relation.uri	http://dx.doi.org/10.1200/JCO.2017.73.7379	de_DE
dc.subject.ddc	610	de_DE
dc.title	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_02250
utue.publikation.seiten	1658-1667	de_DE
utue.personen.roh	Chesney, Jason
utue.personen.roh	Puzanov, Igor
utue.personen.roh	Collichio, Frances
utue.personen.roh	Singh, Parminder
utue.personen.roh	Milhem, Mohammed M.
utue.personen.roh	Glaspy, John
utue.personen.roh	Hamid, Omid
utue.personen.roh	Ross, Merrick
utue.personen.roh	Friedlander, Philip
utue.personen.roh	Garbe, Claus
utue.personen.roh	Logan, Theodore F.
utue.personen.roh	Hauschild, Axel
utue.personen.roh	Lebbe, Celeste
utue.personen.roh	Chen, Lisa
utue.personen.roh	Kim, Jenny J.
utue.personen.roh	Gansert, Jennifer
utue.personen.roh	Andtbacka, Robert H. I.
utue.personen.roh	Kaufman, Howard L.
dcterms.isPartOf.ZSTitelID	Journal of Clinical Oncology	de_DE
dcterms.isPartOf.ZS-Issue	17	de_DE
dcterms.isPartOf.ZS-Volume	36	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE